Fitzpatrick S L, LaChance M P, Schultz G S
Cancer Res. 1984 Aug;44(8):3442-7.
Epidermal growth factor (EGF) may play a role in regulating growth of breast cancer cells in vivo. We have examined the action of EGF on breast cancer cells in vitro and characterized the EGF receptor as a model system for its action in vivo. All of the fourteen breast cancer cell lines which grow attached to culture dishes specifically bound EGF, including one purportedly normal breast line (HBL-100). The one cell line examined which grows as a suspension, DU-4475, did not express measurable levels of EGF binding. The number of EGF binding sites per cell for the different cell lines varied from 200 EGF binding sites/cell (for MDA-MB-436) to 700,000 EGF binding sites/cell (for MDA-MB-231), with most cell lines having approximately 10,000 EGF binding sites/cell. Scatchard analysis of EGF binding to four of the breast cell lines indicated a single class of high-affinity binding sites for MDA-MB-231 cells (Kd = 200 pM; n = 220 fmol of EGF bound/mg of cell protein); and for T-47D cells (Kd = 4 nM, n = 85 fmol of EGF bound/mg of cell protein) and curvilinear plots for MCF-7 cells and HBL-100 cells. The EGF binding to MDA-MB-231 cells was specific for EGF and was maximum after 2 hr at 37 degrees, followed by a progressive loss of cell-associated radio-activity, which was prevented by the action of the lysosomal inhibitory agent chloroquine. Specific covalent binding of 125I-EGF to MDA-MB-231 cells indicated that the EGF receptor had molecular weights of 165,000 and 140,000. MCF-7 cells and T-47D cells grown in serum-free medium supplemented with 10 nM EGF for 3 days had significantly increased protein, DNA, and cell number, whereas MDA-MB-231 and ZR-75-1 cells did not respond significantly to EGF. These results indicate that EGF receptors are consistently expressed by breast cells grown attached to a surface but that some cell lines expressing EGF receptors do not respond mitogenically to EGF. The biochemical characteristics of EGF receptors in MDA-MD-231 breast cells are similar to those observed for EGF receptors in other human tissues.
表皮生长因子(EGF)可能在体内调节乳腺癌细胞的生长中发挥作用。我们已经在体外研究了EGF对乳腺癌细胞的作用,并将EGF受体作为其在体内作用的模型系统进行了表征。所有14种贴壁生长于培养皿的乳腺癌细胞系均能特异性结合EGF,包括一种据称正常的乳腺细胞系(HBL-100)。所检测的一种悬浮生长的细胞系DU-4475未表达可测量水平的EGF结合。不同细胞系每个细胞的EGF结合位点数量从200个EGF结合位点/细胞(MDA-MB-436)到700,000个EGF结合位点/细胞(MDA-MB-231)不等,大多数细胞系约有10,000个EGF结合位点/细胞。对四种乳腺癌细胞系的EGF结合进行Scatchard分析表明,MDA-MB-231细胞有一类单一的高亲和力结合位点(Kd = 200 pM;n = 220 fmol EGF结合/mg细胞蛋白);T-47D细胞(Kd = 4 nM,n = 85 fmol EGF结合/mg细胞蛋白)以及MCF-7细胞和HBL-100细胞呈曲线图谱。MDA-MB-231细胞与EGF的结合对EGF具有特异性,在37℃ 2小时后达到最大值,随后细胞相关放射性逐渐丧失,溶酶体抑制剂氯喹的作用可阻止这种情况。1₂₅I-EGF与MDA-MB-231细胞的特异性共价结合表明,EGF受体的分子量为165,000和140,000。在补充有10 nM EGF的无血清培养基中培养3天的MCF-7细胞和T-47D细胞,其蛋白质、DNA和细胞数量显著增加,而MDA-MB-231和ZR-75-1细胞对EGF无明显反应。这些结果表明,贴壁生长的乳腺细胞始终表达EGF受体,但一些表达EGF受体的细胞系对EGF无促有丝分裂反应。MDA-MD-231乳腺癌细胞中EGF受体的生化特性与在其他人体组织中观察到的EGF受体相似。